drugset / Trial / NCT02859246

Mucinex® for Treatment of Filamentary Keratitis

NCT02859246

Completed 15 enrolled Massachusetts Eye and Ear Infirmary
NaSingle-groupOpen-labelTreatment

Summary

It is a pilot study aimed to determine if oral Mucinex® is effective in reducing the amount of corneal filaments and improving symptomology in subjects with filamentary keratitis.

Timeline

Start
2016-09
Primary completion
2018-07
Completion
2018-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Guaifenesin Small molecule 600 mg Oral

Indications